General Rheumatology

Janssen’s Single-Shot COVID-19 Vaccine Gets Emergency Use Authorization

The EUA was based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.

JAK Inhibitor and Type I Interferon Possible Treatments for COVID-19

Study authors conducted a systematic review and meta-analysis to assess the efficacy of Janus kinase-inhibitors and Type I interferons as potential antiviral candidates for the treatment of COVID-19.

Text Message System Useful for Monitoring Postoperative Opioid Use

A text message system can monitor postoperative opioid use and shows that many prescribed opioid tablets are unused.

IL-1, IL-6 Inhibition in Patients With COVID-19 and Hyperinflammation Assessed

Researchers compared IL-1 and IL-6 inhibition vs standard management in hospitalized patients with COVID-19, respiratory insufficiency, and hyperinflammation.

Moderna Outlines Strategy for SARS-CoV-2 Variants; Ships Variant Booster to NIH for Testing

The NIAID will evaluate the vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant, B.1.351.

Immune Checkpoint Inhibitors Need Not Be Withheld in Patients With Autoimmune Disease

For patients with advanced melanoma, response to immune checkpoint inhibitors is similar for those with and without preexisting autoimmune disease.

Small Study Tests Colchicine for Moderate to Severe COVID-19

For patients with moderate-to-severe COVID-19, colchicine reduces the length of supplemental oxygen therapy and hospitalization.

FDA Approves 3D Printed Implant for Avascular Necrosis of the Talus

The FDA has approved the Patient Specific Talus Spacer for humanitarian use in the treatment of avascular necrosis of the ankle joint.

ACR Releases COVID-19 Vaccine Clinical Guidance for Patients With Rheumatic and Musculoskeletal Diseases

The American College of Rheumatology developed clinical guidance for the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases.

FDA Approves Emergency Use of Bamlanivimab Plus Etesevimab for COVID-19

The FDA has issued an Emergency Use Authorization for Lilly’s SARS-CoV-2 neutralizing antibodies bamlanivimab plus etesevimab.

Blood Types O and Rh-Negative Protective Against COVID-19

Investigators determined whether ABO and Rh blood groups were associated with risk for SARS-CoV-2 infection and severe COVID-19 illness.

Increase in Hydroxychloroquine-Related Adverse Reactions in 2020

The number of ADRs associated with hydroxychloroquine and chloroquine more than doubled in 2020 compared with 2018 and 2019.

Janssen Requests Emergency Use Authorization for Single-Shot COVID-19 Vaccine

The EUA submission is based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.

Return to Full Functionality After Hip Fracture Takes 2 to 3 Years

Hip fracture survivors experience notable declines in function and well-being in the first year.

Case Study: Inflammatory Disease Presenting as a Doughnut Sign

Case study of a 37-year-old woman with a unique presentation of an inflammatory disease.